Search

Your search keyword '"Pirmohamed M"' showing total 40 results

Search Constraints

Start Over You searched for: Author "Pirmohamed M" Remove constraint Author: "Pirmohamed M" Topic anticoagulants Remove constraint Topic: anticoagulants
40 results on '"Pirmohamed M"'

Search Results

1. Stable warfarin dose prediction in sub-Saharan African patients: A machine-learning approach and external validation of a clinical dose-initiation algorithm.

2. Improving anticoagulation in sub-Saharan Africa: What are the challenges and how can we overcome them?

3. Warfarin dosing algorithms: A systematic review.

4. Genetic Factors Influencing Warfarin Dose in Black-African Patients: A Systematic Review and Meta-Analysis.

5. A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa.

6. Processes and barriers to implementation of point-of-care genotype-guided dosing of warfarin into UK outpatient anticoagulation clinics.

7. Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study.

8. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.

9. Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden.

10. A multi-factorial analysis of response to warfarin in a UK prospective cohort.

11. Genotype-guided versus standard vitamin K antagonist dosing algorithms in patients initiating anticoagulation. A systematic review and meta-analysis.

12. Variation in warfarin prescribing and dosing in the UK: a national survey of anticoagulation clinics.

13. Quality of life in patients with venous thromboembolism and atrial fibrillation treated with coumarin anticoagulants.

14. Oral anticoagulation: a critique of recent advances and controversies.

15. Genome-wide association study of warfarin maintenance dose in a Brazilian sample.

16. Patients benefit from genetics-guided coumarin anticoagulant therapy.

17. Genotype-guided dosing of vitamin K antagonists.

18. Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation.

19. A randomized trial of genotype-guided dosing of warfarin.

20. Adherence and variability in warfarin dose requirements: assessment in a prospective cohort.

21. Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs.

22. Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy.

23. The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors.

24. A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy.

25. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses.

26. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.

27. A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives.

28. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups.

29. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design.

30. Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy.

31. Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study.

32. Spontaneous hemothorax following anticoagulation with low-molecular-weight heparin.

33. Pharmacogenetics of warfarin: current status and future challenges.

34. Warfarin pharmacogenetics: economic considerations.

36. The future prospects of pharmacogenetics in oral anticoagulation therapy.

37. Possible interaction between warfarin and cranberry juice.

38. Comparative Effectiveness of Dabigatran, Rivaroxaban, Apixaban, and Warfarin in the Management of Patients With Nonvalvular Atrial Fibrillation.

39. Integration of Genetic, Clinical, and INR Data to Refine Warfarin Dosing.

40. Patients Benefit From Genetics-Guided Coumarin Anticoagulant Therapy.

Catalog

Books, media, physical & digital resources